Argenx SE (ARGX)
Stock Price:
$252.24 USD
-4.56 (-1.78%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
After-hours: $260.00 +7.76 (3.08%) Oct 22, 4:01 PM
Key Info
| Market Cap |
11.86B |
| Revenue (ttm) |
78.41M |
| Net Income (ttm) |
-162.97M |
| Shares Out |
47.01M |
| EPS (ttm) |
-1.73 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 22, 2020 |
| Last Price |
$252.24 |
| Previous Close |
$256.80 |
| Change ($) |
-4.56 |
| Change (%) |
-1.78% |
| Day's Open |
246.16 |
| Day's Range |
245.72 - 255.53 |
| Day's Volume |
212,638 |
| 52-Week Range |
103.75 - 284.00 |
More Stats
| Market Cap |
11.86B |
| Enterprise Value |
10.36B |
| Earnings Date (est) |
Mar 4, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
47.01M |
| Float |
46.93M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-1.73 |
| FCF / Share |
4.00 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
1.30% |
| Payout Ratio |
n/a |
| Shares Short |
1.07M |
| Short Ratio |
5.05 |
| Short % of Float |
2.29% |
| Beta |
0.86 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
76.77 |
| PS Ratio |
151.23 |
| PB Ratio |
6.57 |
| Revenue |
78.41M |
| Operating Income |
-201.85M |
| Net Income |
-162.97M |
| Free Cash Flow |
154.45M |
| Net Cash |
1.49B |
| Net Cash / Share |
31.78 |
| Gross Margin |
100.00% |
| Operating Margin |
-257.44% |
| Profit Margin |
-233.50% |
| FCF Margin |
196.98% |
| ROA |
-13.50% |
| ROE |
-28.35% |
| ROIC |
-27.20% |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (20)
| Buy |
13 |
| Overweight |
2 |
| Hold |
5 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$267.70*
(6.13% upside)
Low
209
Current: $252.24
High
300
Target: 267.70
*Average 12-month USD price target from 20 stock analysts.
Financial Performance
Financial numbers in millions EUR.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | 69.78 | 21.48 | 36.42 | 14.71 | 6.85 |
| Revenue Growth | 224.84% | -41.01% | 147.5% | 114.66% | - |
| Gross Profit | 69.78 | 21.48 | 36.42 | 14.71 | 6.85 |
| Operating Income | -180 | -81.85 | -22.93 | -21.42 | -15.61 |
| Net Income | -163 | -66.64 | -28.08 | -21.37 | -15.31 |
| Shares Outstanding | 38.62 | 33.42 | 24.61 | 18.82 | 15.73 |
| Earnings Per Share | -4.22 | -1.99 | -1.14 | -1.14 | -0.97 |
| Operating Cash Flow | 139 | -53.27 | -36.55 | 10.60 | -13.90 |
| Capital Expenditures | -1.60 | -0.62 | -0.35 | -0.84 | -0.27 |
| Free Cash Flow | 137 | -53.90 | -36.89 | 9.76 | -14.17 |
| Cash & Equivalents | 1,336 | 566 | 361 | 97.51 | 42.33 |
| Total Debt | 6.51 | - | - | - | - |
| Net Cash / Debt | 1,329 | 566 | 361 | 97.51 | 42.33 |
| Assets | 1,433 | 578 | 371 | 106 | 45.96 |
| Liabilities | 383 | 40.06 | 25.98 | 42.40 | 8.68 |
| Book Value | 1,051 | 538 | 345 | 63.37 | 37.28 |
Numbers in millions EUR, except per-share numbers.
Company Details
| Full Name |
Argenx SE |
| Country |
Netherlands |
| Employees |
186 |
| CEO |
Tim van Hauwermeiren |
Stock Information
| Ticker Symbol |
ARGX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ARGX |
| IPO Date |
May 18, 2017 |
Description
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis in Phase 3; immune thrombocytopenia in Phase 3; pemphigus vulgaris in Phase 2; chronic inflammatory demyelinating polyneuropathy in Phase 2; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase 2 clinical stage in hematological cancer indications; and preclinical products, including ARGX-117 with therapeutic potential in both orphan and large autoimmune inflammatory diseases in and ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation and ARGX-115 for cancer immunotherapy, which are in Phase 1 clinical stages; and ARGX-116 for the treatment of dyslipidemia and ARGX-114 for treating fibrosis, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.